Accelerate to discover
Related topics
Preclinical lung imaging offers effective evaluation of drug candidates
Mar 1, 2021
The incidence of respiratory disease is increasing throughout the world, and the demand for safe, effective drugs to...
Curiox Laminar Wash technology to become a gold standard for TotalSeq Protocol.
Feb 15, 2021
Curiox Laminar Wash technology has been added as part of the official BioLegend TotalSeq Protocol. It makes processing...
Amnis CellStream's new software features - now better than ever
Feb 12, 2021
It's finally here, and better than ever - Amnis CellStream's Acquisition and Analysis Software update increases ease of...
Towards silent and distortion-free fMRI with Zero Echo Time MRI
Feb 9, 2021
By using fast imaging techniques capable of scanning large brain regions within short durations, continuous snapshots...
STAT Protein Phosphorylation in CD4+ T Cells using the CellStream flow cytometer
Jan 21, 2021
Cytokine-induced protein phosphorylation is a key cell signaling event within the immune system that modulates diverse...
Introducing Cytek cFluor, 14 Colors Immunoprofiling Kit
Jan 19, 2021
Cytek cFluor Immunoprofiling Kit allows for the identification of helper T cells, cytotoxic T cells, B cells, NK cells...
A Glimpse on physiological monitoring for the in vivo SKYSCAN Systems
Jan 14, 2021
This past year has proven once again that in vivo imaging is an important aspect in the microCT world. For longitudinal...
High gain mode now available on the Amnis ImageStreamX Mk II
Dec 31, 2020
Increase camera gain during data acquisition and dramatically increase photonic sensitivity with High Gain mode, a new...
May 18, 2016
With the increasing need for new therapies for cancer, autoimmune disorders and Alzheimer’s disease, monoclonal antibodies are proving very successful due to their high affinity and specificity for their target antigens. In cancer, for example, their first use was as antagonists of oncogenic receptor tyrosine kinases, but today monoclonal antibodies have emerged as vehicles for the targeted delivery of potent chemotherapeutic agents and as powerful tools to manipulate anticancer immune responses. Currently,
more than 30 antibody therapeutics are marketed worldwide. Some analysts predict that, given the rate of current revenue growth and potential new approvals, the global market could reach $58 billion by 2016. In addition, there are hundreds of monoclonal antibody-based biologic drugs in various phases of clinical trials worldwide.
Get more info
Brand profile
IntelliCyt Corporation's high throughput flow technology is the first to enable screening suspension cells, beads, microbes and mixtures.
More info at:
www.intellicyt.com/
BioFocus newsletter
Register to receive Brand new technology development, Important product updates, Interesting scientific events and more!
BioTech a.s. © 2014
Designed & developed by imagineit
Technologies
